SCHEMBL30714673

SCHEMBL30714673

Cn1nc2ccc(OCc3cccnc3C(F)(F)F)cc2c1C(=O)NC1(C(N)=O)COC1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CD38 P28907 1/20 0.35
GRM2 Q14416 1/20 0.34
OPRL1 P41146 2/20 0.34
MGAT2 Q10469 1/20 0.32
ADAM17 P78536 4/20 0.31
MMP3 P08254 1/20 0.31
MAPT P10636 3/20 0.30
L3MBTL1 Q9Y468 2/20 0.30
CACNA1G O43497 1/20 0.30
CACNA1H O95180 1/20 0.30
CACNA1I Q9P0X4 1/20 0.30
POLB P06746 1/20 0.30
MEN1 O00255 1/20 0.30
LMNA P02545 1/20 0.30
GAA P10253 1/20 0.30
HTT P42858 1/20 0.30
KMT2A Q03164 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30
MCHR1 Q99705 2/20 0.30
HSD17B13 Q7Z5P4 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30714574 0.94 CD38 (0.33) CD38GRM2OPRL1MGAT2ADAM17
SCHEMBL30714569 0.89 CYP4F2 (0.34) CD38OPRL1ADAM17MMP3MAPT
SCHEMBL26696044 0.89 CYP4F2 (0.34) CD38OPRL1ADAM17MMP3MAPT
SCHEMBL26696014 0.88 ANO1 (0.33) CD38GRM2OPRL1ADAM17MMP3
SCHEMBL30714572 0.88 ANO1 (0.33) CD38GRM2OPRL1ADAM17MMP3
SCHEMBL26875162 0.88 GRM2 (0.33) CD38GRM2OPRL1ADAM17MMP3
SCHEMBL30714552 0.87 ADAM17 (0.31) OPRL1ADAM17MMP3MAPTCACNA1G
SCHEMBL30714680 0.84 SCN9A (0.38) GRM2OPRL1ADAM17CACNA1GCACNA1H
SCHEMBL30714699 0.84 ADAM17 (0.39) ADAM17MMP3SCN9A
SCHEMBL30714603 0.83 ADAM17 (0.34) GRM2OPRL1ADAM17CACNA1GCACNA1H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250376461-A1 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS UNIV LEUVEN KATH (BE) 2025-12-11 US disclosed
EP-4499624-A2 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS Katholieke Universiteit Leuven KU Leuven Research & Development (BE) 2025-02-05 EP disclosed
WO-2023230540-A2 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250376461-A1 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS TRPV3, TRPM2, TRPV1 CD38 1480/4885GRM2 696/4885OPRL1 112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.